Loxoprofen sodium

SKU: orb1710698

Description

Loxoprofen sodium is a dual COX-1/COX-2 inhibitor that suppresses prostaglandin synthesis. It exhibits anti-inflammatory and potential antitumor properties, making it a useful research tool for studying atherosclerosis and related inflammatory processes in both cellular and animal models.

Research Area

Immunology & Inflammation, Neuroscience

Key Properties

• CAS Number: 80382-23-6
• MW: 268.2834
• Purity: >99.99% (May vary between batches)
• Formula: C₁₅H₁₇NaO₃
• SMILES: [Na+].CC(C([O-])=O)C1=CC=C(CC2CCCC2=O)C=C1
• Target: COX
• Solubility: DMSO:13 mg/mL (48.46 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (3.73 mM);H2O:90 mg/mL (335.47 mM)

Bioactivity

• Target IC50:
  COX-2:13.5 μM|COX-1:6.5 μM
• In Vivo:
  Loxoprofen reduces acetic acid-induced writhing in mice and carrageenan-induced paw edema and LPS-induced fever in rats (ED30s = 20.1, 0.7, and 2.79 mg/kg, respectively). Loxoprofen sodium (4 mg/kg/day; p.o.; 1 or 8 weeks) reduces atherosclerosis in mice by reducing inflammation. Loxoprofen sodium (60 μg/mL; p.o.; 24 days) suppresses mouse tumor growth by inhibiting VEGF.
• In Vitro:
  Loxoprofen sodium, an anti-inflammatory prodrug, is a nonselective COX inhibitor with IC50s of 6.5 and 13.5μM for COX-1 and COX-2 in human whole blood assays, respectively. Loxoprofen sodium is a non-selective cyclooxygenase inhibitor that is widely used for the research of pain and inflammation caused by chronic and transitory conditions. In addition, LOX sodium can also be converted into an inactive hydroxylated metabolite (OH-LOXs) by cytochrome P450 (CYP).'

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

COX-1, COX-2, CS 600, CS600, CS-600, Loxoprofen, Loxoprofen sodium

Compound Identifiers

PubChem CID

23663407